ScreenerHero

BFRI Biofrontera Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · biofrontera-us.com
0.9320USD+4.61%Mkt Cap: 13.84M $P/E: —

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL l…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD

Key Statistics

Company
Market Cap13.84M USD
Enterprise Value16.68M USD
Revenue (TTM)46.17M USD
Gross Profit30.74M USD
Net Income (TTM)-10.54M USD
Revenue/Share3.92 USD
Last Price0.9320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees84
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)2.17
PEG—
EV/EBITDA-2.79
EV/Revenue0.36
P/S0.30
P/B2.22
EPS (TTM)-0.45
EPS (Forward)0.43
52W Range
0.555034% of range1.660
52W High1.660 USD
52W Low0.5550 USD
Profitability
Gross Margin73.71%
Oper. Margin-4.37%
EBITDA Margin-12.93%
Profit Margin-25.26%
ROE-100.53%
ROA-36.89%
Growth
Revenue Growth32.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.36M USD
CapEx (TTM)2.00K USD
FCF Margin-16.45%
FCF Yield-54.89%
Net Debt2.84M USD
Net Debt/EBITDA-0.48
Balance Sheet
Debt/Equity0.59
Current Ratio1.18
Quick Ratio1.00
Book Value/Sh0.42 USD
Cash/Share0.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 5, 2023
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+543.8%
Target Range3.000 USD – 9.000 USD
3.000+543.8% to mean9.000
# Analysts2
Ownership
Shares Out.14.85M
Float11.82M
Insiders11.99%
Institutions20.72%
Short Interest
Short Ratio0.5d
Short % Float3.24%
Short % Out.3.13%
Shares Short464.82K
Short (prev mo.)32.91K
Technical
SMA 501.303 (-28.5%)
SMA 2001.024 (-8.9%)
Beta0.88
S&P 52W Chg16.45%
Avg Vol (30d)655.83K
Avg Vol (10d)361.52K
Technical Indicators
RSI (14)32.7
MACD-0.1009
MACD Signal-0.0601
MACD Hist.-0.0408
BB Upper1.664 USD
BB Middle1.231 USD
BB Lower0.7991 USD
BB Width70.22%
ATR (14)0.1025 USD
Vol Ratio (20d)0.59x